On June 12, Medline Inc declined 5.29% in regular trading, trading at $35.185/share, with turnover of $55.21 million.

On the news front, the U.S. Food and Drug Administration issued a warning letter to Medline on May 28, citing serious violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals at the company's Illinois facility. This marks the second FDA warning letter issued to the company within a two-month span. Medline is required to respond within 15 business days detailing corrective actions taken, or it may face regulatory penalties including suspension of export certificate issuance.

Compounding regulatory pressure, the company is also facing a securities fraud investigation. The overlap of multiple regulatory risks has continued to weigh on the stock price, with shares remaining under sustained selling pressure as investors assess the potential operational and legal consequences of these developments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)